- Home
- QLGN vs EYEN Comparison
QLGN vs EYEN Comparison
Compare QLGN & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- EYEN
- Stock Information
- Founded
- QLGN 1996
- EYEN 2014
- Country
- QLGN United States
- EYEN United States
- Employees
- QLGN N/A
- EYEN N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- EYEN Health Care
- Exchange
- QLGN Nasdaq
- EYEN Nasdaq
- Market Cap
- QLGN 2.8M
- EYEN 2.9M
- IPO Year
- QLGN N/A
- EYEN 2018
- Fundamental
- Price
- QLGN $3.16
- EYEN $15.75
- Analyst Decision
- QLGN
- EYEN Hold
- Analyst Count
- QLGN 0
- EYEN 4
- Target Price
- QLGN N/A
- EYEN $2.00
- AVG Volume (30 Days)
- QLGN 10.7K
- EYEN 9.4M
- Earning Date
- QLGN 08-13-2025
- EYEN 08-11-2025
- Dividend Yield
- QLGN N/A
- EYEN N/A
- EPS Growth
- QLGN N/A
- EYEN N/A
- EPS
- QLGN N/A
- EYEN N/A
- Revenue
- QLGN N/A
- EYEN $67,063.00
- Revenue This Year
- QLGN N/A
- EYEN $7,680.45
- Revenue Next Year
- QLGN N/A
- EYEN $315.38
- P/E Ratio
- QLGN N/A
- EYEN N/A
- Revenue Growth
- QLGN N/A
- EYEN 663.82
- 52 Week Low
- QLGN $2.85
- EYEN $0.85
- 52 Week High
- QLGN $29.44
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- QLGN 32.55
- EYEN 77.63
- Support Level
- QLGN $3.37
- EYEN $7.50
- Resistance Level
- QLGN $3.70
- EYEN $14.33
- Average True Range (ATR)
- QLGN 0.21
- EYEN 2.92
- MACD
- QLGN -0.05
- EYEN 0.86
- Stochastic Oscillator
- QLGN 0.00
- EYEN 90.51
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.